Latest News - Multiple Sclerosis & Immune Disorders

Wednesday, October 04, 2017 | FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders, Product Launches and Updates

FDA Greenlights Two Generic Glatiramer Acetate Formulations for Relapsing MS

The FDA approved Mylan’s generic versions of glatiramer acetate, including a three-times weekly 40mg/mL formulation of glatiramer acetate and a once-daily 20mg/mL formulation…

Read the full story

Thursday, September 14, 2017 | Multiple Sclerosis & Immune Disorders, Research and Publications

Vitamin D Levels Tied to Risk of MS

Examining vitamin D levels in the blood may help predict whether a person is at risk of developing multiple sclerosis (MS), according to a large new study published Neurology (September 13). Usin…

Read the full story

Thursday, September 07, 2017 | Imaging & Testing, Multiple Sclerosis & Immune Disorders, Research and Publications

Project ALS and Amylyx Team Up to Test Phase 2 Compound

Project ALS and Amylyx Pharmaceuticals are collaborating to undertake pre-clinical studies to advance the understanding of Amylyx's oral compound AMX0035 for the treatment of amyotrophic lateral s…

Read the full story

Tuesday, September 05, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Merck & Co. H

CLARITY Extension: Annual Short-Course Therapy with Investigational Oral Agent Effective in Relapsing MS

New results suggest that patients with relapsing multiple sclerosis (MS) treated with two annual short courses of the investigational cladribine tablets (EMD Serono) may have similar clinical benefits…

Read the full story

Tuesday, August 15, 2017 | Multiple Sclerosis & Immune Disorders, Research and Publications

Gut Bacteria May Play Preventive Role in MS

New findings support the increasingly prominent hypothesis that gut bacteria play a role in autoimmune diseases such as multiple sclerosis (MS). Specifically, a study published in Cell Reports (Aug;20…

Read the full story

Tuesday, August 08, 2017 | FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders, Personnel/Company News

Recently Approved ALS Treatment Radicava Now Available

Radicava (edaravone, Mitsubishi Tanabe Pharma America), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), is now available for treatment in th…

Read the full story

Tuesday, May 23, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications

Celgene’s Investigational MS Agent Reduces Annual Relapse Rate but Falls Short of Disability Endpoint in Phase 3 Trial

New Phase 3 findings suggest that Celgene’s investigational ozanimod for relapsing multiple sclerosis (MS) reduces annualized relapse rate in a clinically meaningful way but does not significant…

Read the full story

Friday, May 05, 2017 | FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications

FDA Greenlights First New Treatment for ALS in More than Two Decades

The FDA has approved Radicava (edaravone, MT Pharma), as an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS). Radicava is the first treatment approved for the treatment of A…

Read the full story

Thursday, May 04, 2017 | Multiple Sclerosis & Immune Disorders, Product Launches and Updates, Research and Publications

MS Topography App Launches

A new app that offers a new, visual way of understanding multiple sclerosis (MS) was recently launched at the American Academy of Neurology Annual Meeting in Boston. The app is a disease simulation th…

Read the full story

Wednesday, April 26, 2017 | Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech

AAN 2017 Meeting: New Data Reinforce Efficacy of Ocrelizumab

New data presented at the American Academy of Neurology (AAN) Annual Meeting in Boston show the benefits of ocrelizumab in relapsing multiple sclerosis (MS). In a pooled analysis of Phase 3 …

Read the full story

Tuesday, April 04, 2017 | FDA Approval/Clearance, Movement Disorders, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials

New Therapy for Chorea Associated with Huntington’s Disease Wins FDA Approval

The FDA approved Austedo (deutetrabenazine, Teva Pharmaceuticals) tablets for the treatment of chorea associated with Huntington’s disease (HD), making it just the second product approved for th…

Read the full story

Tuesday, March 28, 2017 | Clinical Trials, FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders, Phase 3/4 Trials, Research and Publications, Genentech, Roche

Ocrevus Receives FDA Greenlight for Relapsing, Primary Progressive Forms of Multiple Sclerosis

The FDA has approved Ocrevus (ocrelizumab, Roche/Genentech) for the treatment of both relapsing and primary progressive forms of multiple sclerosis. Ocrelizumab is a humanized antibody that …

Read the full story

Friday, February 17, 2017 | Multiple Sclerosis & Immune Disorders

FDA Accepts NDA Filing for MT Pharma’s Investigational ALS Treatment

The FDA accepted the Mitsubishi Tanabe Pharma’s New Drug Application (NDA) for edaravone (MCI-186), an intravenous treatment for amyotrophic lateral sclerosis (ALS). Edaravone is described as a …

Read the full story

Friday, February 10, 2017 | FDA Approval/Clearance, Multiple Sclerosis & Immune Disorders

New Corticosteroid Approved for Duchenne Muscular Dystrophy

The FDA approved Emflaza (deflazacort) tablets and oral suspension to treat patients age five years and older with Duchenne muscular dystrophy (DMD). Emflaza is the first FDA approved corticosteroid t…

Read the full story

Tuesday, February 07, 2017 | Multiple Sclerosis & Immune Disorders, Research and Publications

Blood Biomarker for Quick and Accurate Prognosis of MS Identified

A newly discovered blood biomarker may aid physicians in identifying the type of multiple sclerosis (MS) in their patients. In a study recently published in Scientific Reports, investigators evaluated…

Read the full story
Load More